Supporting blood bank screening, medical diagnostics and drug discovery services, Lab21’s products division manufactures immunodiagnostic kits and reagents for healthcare providers, pharmaceutical and diagnostic companies.
Lab21 CFO Susan Lowther said after three years of developing clinical service business in South Carolina, the company has taken the decision to sell the laboratory operations in Greenville and Columbia, US.
"This sale does not impact our core strategy to focus on personalized medicine and Lab21 will continue to focus on diagnostic content strategy opportunities within the US market," Lowther added.’
The financial details of the acquisition have not been revealed.